HUTCHMED (HCM) News Today $14.62 -0.47 (-3.11%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. reduced its stake in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 38.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,109 shares of the company'sMarch 23 at 3:29 AM | marketbeat.comHUTCHMED (NASDAQ:HCM) Rating Increased to Buy at StockNews.comStockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a research note on Friday.March 22 at 11:17 PM | marketbeat.comHUTCHMED (NASDAQ:HCM) Stock Price Down 5.7% - Time to Sell?HUTCHMED (NASDAQ:HCM) Stock Price Down 5.7% - Should You Sell?March 22 at 12:53 PM | marketbeat.comHUTCHMED (NASDAQ:HCM) Upgraded by StockNews.com to Buy RatingMarch 22 at 3:51 AM | americanbankingnews.comHutchmed says NDA for Tazverik granted conditional approval in ChinaMarch 21, 2025 | markets.businessinsider.comHUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular LymphomaMarch 21, 2025 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Dermata Therapeutics (DRMA), HUTCHMED (HCM)March 21, 2025 | markets.businessinsider.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - What's Next?HUTCHMED (NASDAQ:HCM) Shares Gap Up - What's Next?March 20, 2025 | marketbeat.comHUTCHMED and Innovent report success in renal cancer studyMarch 20, 2025 | investing.comIntended Retirement of Independent Non-executive Directors and changes of composition of board committeesMarch 20, 2025 | globenewswire.comHutchmed reports FY24 EPS 22c vs. 59c last yearMarch 20, 2025 | markets.businessinsider.comHutchmed sees FY25 Oncology/Immunology revenue $350M-$450MMarch 20, 2025 | markets.businessinsider.comHUTCHMED’s Savolitinib Shows Promising Results in Lung Cancer TrialsMarch 19, 2025 | tipranks.comHUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025March 19, 2025 | globenewswire.comHUTCHMED (China) Limited: HUTCHMED Reports 2024 Full Year Results and Provides Business UpdatesMarch 19, 2025 | finanznachrichten.deHUTCHMED Reports 2024 Full Year Results and Provides Business UpdatesMarch 19, 2025 | markets.businessinsider.comHutchmed spikes after cancer trial win despite 2024 revenue missMarch 19, 2025 | msn.comHUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | seekingalpha.comHUTCHMED (China) Limited 2024 Q4 - Results - Earnings Call PresentationMarch 19, 2025 | seekingalpha.comHUTCHMED Reports 2024 Full Year Results and Provides Business UpdatesMarch 19, 2025 | globenewswire.comInnovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in ChinaMarch 18, 2025 | prnewswire.comHUTCHMED and Innovent’s Combination Therapy Shows Promise in Advanced Renal Cell CarcinomaMarch 18, 2025 | tipranks.comHUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in ChinaMarch 18, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - What's Next?HUTCHMED (NASDAQ:HCM) Shares Gap Down - Should You Sell?March 18, 2025 | marketbeat.comHUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three yearsMarch 10, 2025 | finance.yahoo.comHUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in ChinaMarch 6, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Share Price Crosses Above Fifty Day Moving Average - Time to Sell?HUTCHMED (NASDAQ:HCM) Stock Price Crosses Above 50 Day Moving Average - Here's WhyMarch 6, 2025 | marketbeat.comHUTCHMED Appoints Alvin Wong as Independent Non-executive DirectorMarch 5, 2025 | tipranks.comHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteeMarch 5, 2025 | globenewswire.comHUTCHMED Updates on Disposal of Shanghai Hutchison Pharmaceuticals StakeFebruary 28, 2025 | tipranks.comHUTCHMED (NASDAQ:HCM) Stock Price Up 6.3% - Here's WhyHUTCHMED (NASDAQ:HCM) Stock Price Up 6.3% - What's Next?February 22, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Should You Buy?HUTCHMED (NASDAQ:HCM) Shares Gap Up - Here's WhyFebruary 20, 2025 | marketbeat.comHUTCHMED to Announce 2024 Final ResultsFebruary 19, 2025 | globenewswire.comABC Arbitrage SA Makes New $500,000 Investment in HUTCHMED (China) Limited (NASDAQ:HCM)ABC Arbitrage SA acquired a new position in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 34,710 shares of the company's stock, valued at approximately $500,000. A number of other insFebruary 16, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Reaches New 52-Week Low - Should You Sell?HUTCHMED (NASDAQ:HCM) Hits New 1-Year Low - Here's What HappenedFebruary 12, 2025 | marketbeat.comBank of America Securities Remains a Buy on HUTCHMED (HCM)February 11, 2025 | markets.businessinsider.comHutchmed price target raised to $27 from $26 at BofAFebruary 11, 2025 | markets.businessinsider.com46,676 Shares in HUTCHMED (China) Limited (NASDAQ:HCM) Acquired by XY Capital LtdXY Capital Ltd bought a new position in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 46,676 shares of the company's stock, valued at approxiFebruary 10, 2025 | marketbeat.comHUTCHMED (China) Limited (NASDAQ:HCM) Short Interest Down 12.5% in JanuaryHUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 412,700 shares, a drop of 12.5% from the December 31st total of 471,700 shares. Based on an average daily volume of 78,100 shares, the days-to-cover ratio is presently 5.3 days.February 1, 2025 | marketbeat.comDespite A Promising Future For Hutchmed, We Have Concerns About Development Of The Share Price (Rating Downgrade)January 30, 2025 | seekingalpha.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's What HappenedHUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?January 23, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume - Here's What HappenedHUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume - Here's WhyJanuary 16, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Should You Sell?HUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's WhyJanuary 15, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Stock Price Passes Below 50 Day Moving Average - What's Next?HUTCHMED (NASDAQ:HCM) Share Price Crosses Below 50 Day Moving Average - Here's What HappenedJanuary 15, 2025 | marketbeat.comHutchmed announces NMPA approval for Orpathys supplemental new drug applicationJanuary 14, 2025 | markets.businessinsider.comHUTCHMED’s ORPATHYS® Receives Full NMPA Approval for Expanded NSCLC TreatmentJanuary 13, 2025 | tipranks.comHUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCJanuary 13, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Trading Down 4.5% - Should You Sell?HUTCHMED (NASDAQ:HCM) Stock Price Down 4.5% - Here's WhyJanuary 7, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume - Still a Buy?HUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume - Still a Buy?January 6, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Here's What HappenedHUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?January 2, 2025 | marketbeat.com Remove Ads Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address HCM Media Mentions By Week HCM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HCM News Sentiment▼0.410.68▲Average Medical News Sentiment HCM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HCM Articles This Week▼243▲HCM Articles Average Week Remove Ads Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ASND News PCVX News QGEN News ROIV News SRPT News RVMD News BBIO News LNTH News TGTX News LEGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HCM) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
